Form 8-K · Current Report · Filed 2025-12-22
DexCom Appoints New CEO Jacob S. Leach Effective January 1, 2026
DexCom, Inc. announced that Jacob S. Leach, currently President and Chief Operating Officer, has been appointed as the new President and Chief Executive Officer, effective January 1, 2026. This follows the resignation of Kevin R. Sayer, effective as of the same date. Leach's new role will come with an annual base salary of $1,150,000, a target bonus opportunity equal to 150% of his base salary, and restricted and performance stock units with a fair value of $7,500,000 each. Leach will also remain eligible for the Company's severance and benefit plans. The Board expects Sayer to return from medical leave around March 2026.
- Filer
- Dexcom Inc. DXCM · NASDAQ
- Filed
- Accession
- 0001093557-25-000291
- CIK
- 0001093557
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Financial Statements and Exhibits
Market reaction
Close before filing
$66.06
Next session
+1.2%
Since filing
+26.3%
Latest close
$83.45
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from DXCM reporting the same item, with the next session's move:
About Dexcom Inc.
Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.
Never miss another DXCM filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.